Dr. Rakesh Kumar Agrawal
MBBS, MD (Radiotherapy)
Senior Consultant & HOD, Radiation Oncology
Andromeda Cancer Hospital
Brief Profile
Dr. Rakesh Kumar Agrawal is a highly experienced Radiation Oncologist with more than 25 years of expertise in treating cancer patients using modern radiotherapy techniques. He has worked with some of India’s most reputed cancer hospitals and has played a key role in establishing and leading advanced radiation oncology departments.
Dr. Agrawal completed his MBBS from S.S. Medical College, Rewa (M.P.) and pursued his MD in Radiotherapy from Pt. JLN Medical College, RCC Raipur, becoming the first MD candidate from the institute. Over his career, he has gained hands-on experience in advanced technologies such as IMRT, IGRT, VMAT, Stereotactic Radiotherapy, and HDR Brachytherapy.
Before joining Andromeda Cancer Hospital, he served as HOD and Senior Consultant at Aditya Birla Memorial Hospital, Pune. He also held senior positions at Apollo Hospitals, Rajiv Gandhi Cancer Institute, and Asian Institute of Medical Sciences, among others.
A strong believer in patient-centric care, Dr. Agrawal combines precision medicine with compassion. His experience in project development and department set-up has been instrumental in shaping cancer care facilities from the ground up.
Education
MBBS – S.S. Medical College, Rewa (M.P.), 1991
MD (Radiotherapy) – Pt. JLN Medical College, RCC Raipur (C.G.), 1998
Professional Experience
2025 – Present: Senior Consultant & HOD, Radiation Oncology, Andromeda Cancer Hospital
2017 – 2025: HOD & Senior Consultant, Radiation Oncology, Aditya Birla Memorial Hospital, Pune
2011 – 2017: Senior Consultant, Radiation Oncology, Apollo Cancer Institute, Bilaspur
2010 – 2011: Consultant, Asian Institute of Medical Sciences & Cancer Centre, Faridabad
2007 – 2009: Consultant, Rajiv Gandhi Cancer Institute & Research Centre, Delhi
2002 – 2007: Junior Consultant, Apollo Cancer Institute, Indraprastha Apollo Hospitals, New Delhi
1998 – 2002: Senior Resident / Clinical Assistant, Rajiv Gandhi Cancer Institute, Delhi
1991 – 1992: Junior Resident (General Medicine), Dr. RML Hospital, New Delhi
Work Experience
Expertise in advanced teletherapy: Simulation, CT-based planning, target contouring, treatment verification with online imaging.
Skilled in Brachytherapy: Intracavitary, interstitial, intraluminal, moulds, and intra-operative implants.
Proficient in managing oncologic emergencies and complete in-patient care.
Extensive experience in department setup: Designing infrastructure, equipment commissioning, team building, and workflow management.
Hands-on training in IMRT & IGRT (Mumbai, Hyderabad, Belgium, Switzerland).
Equipment familiarity: Varian (ClinaciX, Trilogy, Novalis Tx), Elekta (Versa HD, Synergy), Siemens (Primus, Artiste), HDR/LDR brachytherapy units, planning systems (Eclipse, Monaco, Oncentra).
Memberships•Life Member, Association of Radiation Oncologists of India (AROI)
Publications & Research
Dr. Agrawal has authored and co-authored multiple papers and presentations in national and international forums. Select works include:
Role of Amifostine in prevention of xerostomia in head & neck cancers – ASTRO 2000.
Dose-finding study of Paclitaxel with concurrent radiation in locally advanced head & neck cancers – AROI 2001.
Reduction in rectal dose in radical radiotherapy of carcinoma prostate – Nagoya, Japan, 2001.
3D conformal radiotherapy in brain tumours: A physical analysis of “Manual” MLC – AROI 2002.
Comparative study of 389 oesophageal cancer cases treated at RGCI (1996–2000).
Role of Temozolamide in brain metastases with radiation – AROI 2003.
Role of IMRT in complex extracranial targets – Nagoya, Japan, 2004.
Clinical Trial Involvement:
Neoadjuvant chemoradiation in cervical cancer.
Multiple pilot studies in head & neck cancer with Amifostine, GM-CSF, alpha-erythropoietin.
Awards, Achievements & Initiatives
First MD (Radiotherapy) candidate from RCC Raipur.
Instrumental in establishing multiple new radiation oncology departments in leading hospitals.
Actively involved in cancer awareness, academic teaching, tumor boards, and clinical research.